Special Issues
Table of Content

Advances in Cancer Therapeutics

Submission Deadline: 31 December 2023 (closed) View: 141

Guest Editors

Prof. Dr. Riffat Mehboob, Lahore Medical Research Center, Lahore, Pakistan. E-mail: mehboob.riffat@gmail.com

Prof. Dr. Fridoon Jawad Ahmad, University of health sciences, Lahore, Pakistan. E-mail: drfridoon@yahoo.com

Prof. Dr. Imrana Tanvir, Faculty of Medicine in Rabigh, Rabigh, Saudi Arabia. E-mail: imrana_tanvir@yahoo.com

Prof. Dr. Muhammad Akram Tariq, Mirpur University of Science and Technology, Pakistan. E-mail: akram@soe.ucsc.edu

Summary

Cancer is the leading cause of worldwide mortalities. Its treatment has always remained challenging due to its complicated aetiology, underlying mechanisms, several pathways controlling the same disease causing gene, complex genetics and influence of environmental factors. Although a great advancement in medicine has led to better management of cancer, improved diagnostics and therapies, still a lot needs to be done in this regard. Prevalence and deaths have been on an increasing verge despite all the collective efforts. Latest technologies such as gene therapy, extracellular vesicles, nanotechnology has revolutionized the cancer treatment.

In this issue we will publish studies related to all kind of therapeutic strategies to understand where are we standing now! Original articles, experimental studies, clinical studies, review articles, opinion articles are welcome.

 

Articles in these areas or related to therapies are encouraged.

 

-Targeting Cancer metabolism for cancer therapy

-Targeting the proliferative markers such as Ki67 as cancer therapy

-Mammalian target of Rapamycin (mTOR) as a potential therapeutic strategy

-Novel Peptide biomarkers in cancer diagnostics and therapy

-Natural products in cancer therapy

-Extacellular vesicles/exosomes as diagnostic and therapeutic tool in cancer

-Bacteria mediated cancer therapy

-Prodrugs in cancer therapy

-drug repurposing in cancer therapy

-Nanotechnology in cancer therapy

-Gene editing/ CRISPR-Cas9 in cancer therapy


Keywords

Cancer therapy, Biomarkers, Gene editing,Nanotechnology

Published Papers


  • Open Access

    ARTICLE

    Circ-PAN3 facilitates hepatocellular carcinoma growth via sponging miR-153 and upregulating cyclin D1

    SHUO YU, MIN WANG, XU LI, XINGJUN GUO, RENYI QIN
    Oncology Research, DOI:10.32604/or.2024.046774
    (This article belongs to the Special Issue: Advances in Cancer Therapeutics)
    Abstract Background: Circular RNAs (circRNAs) play a pivotal role in the development and advancement of various cancer types. However, the involvement of circ-PAN3 in hepatocellular carcinoma (HCC) is not well understood. To shed light on this, we conducted a comprehensive study through biochemistry, cell biology, molecular biology, and bioinformatics techniques to investigate the role of circ-PAN3 and its associated pathway in the progression of HCC. Methods: Cell Counting Kit-8 (CCK-8) assay and colony formation assay were utilized to evaluate cell proliferation; Quantitative real-time PCR (RT-qPCR) and Western blot were adopted for assessing mRNA and protein expression;… More >

  • Open Access

    REVIEW

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

    NILAM BHUSARE, MAUSHMI KUMAR
    Oncology Research, Vol.32, No.5, pp. 849-875, 2024, DOI:10.32604/or.2024.047042
    (This article belongs to the Special Issue: Advances in Cancer Therapeutics)
    Abstract Glioblastoma, the most aggressive form of brain tumor, poses significant challenges in terms of treatment success and patient survival. Current treatment modalities for glioblastoma include radiation therapy, surgical intervention, and chemotherapy. Unfortunately, the median survival rate remains dishearteningly low at 12–15 months. One of the major obstacles in treating glioblastoma is the recurrence of tumors, making chemotherapy the primary approach for secondary glioma patients. However, the efficacy of drugs is hampered by the presence of the blood-brain barrier and multidrug resistance mechanisms. Consequently, considerable research efforts have been directed toward understanding the underlying signaling pathways… More >

    Graphic Abstract

    A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases

  • Open Access

    ARTICLE

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

    ROGHAYEH GHORBANI, MAHMOUD GHARBAVI, ALI SHARAFI, ELHAM RISMANI, HAMED REZAEEJAM, YOUSEF MORTAZAVI, BEHROOZ JOHARI
    Oncology Research, Vol.32, No.1, pp. 101-125, 2024, DOI:10.32604/or.2023.044741
    (This article belongs to the Special Issue: Advances in Cancer Therapeutics)
    Abstract In the present study, we investigated the synergistic effects of targeted methotrexate-selenium nanostructure containing Myc decoy oligodeoxynucleotides along with X-irradiation exposure as a combination therapy on LNCaP prostate cancer cells. Myc decoy ODNs were designed based on the promoter of Bcl-2 gene and analyzed by molecular docking and molecular dynamics assays. ODNs were loaded on the synthesized Se@BSA@Chi-MTX nanostructure. The physicochemical characteristics of nanostructures were determined by FTIR, DLS, UV-vis, TEM, EDX, in vitro release, and hemolysis tests. Subsequently, the cytotoxicity properties of them with and without X-irradiation were investigated by uptake, MTT, cell cycle, apoptosis, and… More >

    Graphic Abstract

    Targeted anti-tumor synergistic effects of Myc decoy oligodeoxynucleotides-loaded selenium nanostructure combined with chemoradiotherapy on LNCaP prostate cancer cells

Share Link